About Shasqi

Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies. Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to deliver unprecedented doses precisely focused at the tumor with an uncharacteristically mild safety profile - breaking through the historic ceiling of dose-limiting toxicities. Shasqi's CAPAC Platform is highly modular and can be applied to a broad range of cancer drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.


José M. Mejía Oneto, MD, PhD

Founder & Chief Executive Officer

Sebastian Sanchez de Lozada

Chief Financial Officer

Board of Directors

José M. Mejía Oneto, MD, PhD

Juan Jaen, PhD

Strategic Advisors

Ronald W. Barrett, Ph.D.

CEO at Medikine

Carolyn Bertozzi, Ph.D.

Professor at Stanford

Pamela M. Klein, M.D

Chief Medical Officer at Olema

Lawrence D. Mayer, Ph.D.

Partner at Coulour Biomedical

Glenn Prestwich, Ph.D.

Co-founder at Spinout Space

William J. Rieflin

Executive Chairman at NGM Bio

Nina Shapiro

Sr. Operating Advisor at New Silk Route

Sarah Noonberg, M.D., PH.D.

Chief Medical Officer at Maze Therapeutics

Lisa M. Coussens, Ph.D., FAACR

Professor & Department Chair at OHSU

Max Royzen

Assistant Professor at University at Albany, SUNY

Shasqi and CAPAC™ Origins


Definition: \'shas-kē\ Noun. [fr. Quechua, ca. 1400‘s, also Chasqui, Chaski]

1. Hist. Agile runners that distributed and translated messages and gifts across the vast Incan Empire.

2. A way to activate cancer drugs at specific areas of the body.


Definition: \'qhapaq’\ Noun. [fr. Quechua, ca. 1400‘s, also qhapaq]

1. Mighty, powerful, noble.

2. Click Activated Protodrugs Against Cancer (CAPAC™). A new platform to improve cancer therapies.